000			03837cam a2200409Ii 4500
001			95644
003			ES-MaUEC
005			20230102112714.0
006			m o d
007			cr cnu|||unuuu
008			170324s2017 sz ob 000 0 eng d
020			_a3319505939
020			_a3319505947 _q(electronic bk.)
020			_a9783319505930
020			_a9783319505947 _q(electronic bk.)
020			_z9783319505930 _q(print)
040			_aN$T _cN$T _dYDX _dEBLCP _dGW5XE _dN$T _dOCLCQ _dNJR _dUAB _dOCLCO _dOCLCF _dOCLCO _dIOG _dOCLCO _dAZU _dUPM _dMERER _dESU _dJBG _dIAD _dICW _dICN _dOCLCQ _dOCLCO _dVT2 _dOTZ _dOCLCO _dOCLCQ _dOCLCO _dU3W _dMERUC _dOCLCO _dOCLCA _dES-MaUEC _bspa
050		4	_aR1 _b2017 EB
245	0	0	_aHidradenitis Suppurativa : _ba disease primer _ceditors: Alexa B. Kimball, Gregor B.E. Jemec.
264		1	_aCham, Switzerland _bAdis _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
504			_aIncluye referencias bibliográficas
505	0		_aEditor biographies; Disease Overview; 1.1 Definition; 1.2 Epidemiology; 1.2.1 Incidence; 1.2.2 Prevalence; 1.3 Risk factors; 1.4 Mortality, morbidity, and quality of life; References; 2 Clinical Presentation of Hidradenitis Suppurativa; 2.1 Clinical presentation; 2.2 Types of lesions; 2.3 Involved areas; 2.4 Clinical course; 2.5 Prognosis and disease complications; 2.5.1 Physical impact; 2.5.2 Psychosocial impact; 2.6 Comorbidities and systemic associations; 2.6.1 Obesity and metabolic syndrome; 2.6.2 Smoking; 2.6.3 Follicular occlusion tetrad; 2.6.4 Inflammatory bowel disease.
505	8		_a2.6.5 Arthritis and spondyloarthropathy2.6.6 Genetic syndromes; 2.6.7 Malignancy; References; 3 Pathophysiology of Hidradenitis Suppurativa; 3.1 Pathogenesis; 3.2 Genetics; 3.3 External factors; 3.4 Mechanical factors; 3.5 Endocrinology; 3.6 Inflammation; 3.7 The role of bacteria; 3.8 Immune dysregulation; 3.9 Key points; References; Diagnostic Workup; 4.1 Introduction; 4.2 Classification systems; 4.2.1 Hurley staging; 4.2.2 Modified Hidradenitis Suppurativa Score; 4.2.3 Hidradenitis Physician Global Assessment Scale; 4.2.4 Hidradenitis Suppurativa Clinical Response Score.
505	8		_a4.3 Delay in diagnosis4.4. Differential diagnosis; 4.5 Referral criteria; References; 5 Treatment of Hidradenitis Suppurativa; 5.1 Introduction; 5.2 Preventative measures & lifestyle modifications; 5.3 Medical management; 5.3.1 Topical clindamycin; 5.3.2 Triamcinolone acetonide; 5.3.3 Clobetasol; 5.3.4 Topical resorcinol; 5.3.5 Oral antibiotics; 5.3.6 Hormonal therapy; 5.3.7 Oral retinoids; 5.3.8 Biologic therapies; 5.3.9 Immunosuppressive agents; 5.4 Radiotherapy; 5.5 Light and laser therapy; 5.6 Surgery; 5.7 Conclusion; References; Appendix; Diagnostic workup (tear-off sheet).
520	3		_aA concise but comprehensive pocket handbook that provides an accessible and up-to-date introductory overview of this debilitating skin disease. Written by highly recognizable leaders in the field, this book presents essential information on the pathophysiology, clinical presentation, diagnosis and management strategies and options for hidradenitis suppurativa, forming an ideal resource to increase awareness of this disease among healthcare professionals.
650		7	_aPiel _xEnfermedades _2embne _0(OCoLC)fst01120068 _0 _9168912
700	1		_aJemec, G. B. E. _q(Gregor B. E.), _eeditor literario
700	1		_aKimball, Alexa Boer, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-50594-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95644 _d95644 _x1